Janus Henderson Group PLC Sells 4,781,513 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Janus Henderson Group PLC lowered its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 99.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,839 shares of the company's stock after selling 4,781,513 shares during the quarter. Janus Henderson Group PLC's holdings in Perspective Therapeutics were worth $57,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC lifted its stake in shares of Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock valued at $4,147,000 after buying an additional 800,000 shares during the period. Walleye Capital LLC raised its holdings in Perspective Therapeutics by 2,526.2% in the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock valued at $1,518,000 after acquiring an additional 457,675 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth approximately $834,000. Jump Financial LLC bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth approximately $688,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth approximately $418,000. 54.66% of the stock is owned by institutional investors.

Insider Buying and Selling at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the transaction, the chief executive officer now directly owns 59,383 shares in the company, valued at approximately $133,017.92. This represents a 58.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Robert F. Williamson III bought 38,145 shares of Perspective Therapeutics stock in a transaction on Monday, March 31st. The shares were acquired at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now owns 108,982 shares of the company's stock, valued at approximately $233,221.48. This represents a 53.85% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.52% of the company's stock.

Perspective Therapeutics Trading Down 3.1%

NYSE:CATX traded down $0.09 during mid-day trading on Friday, hitting $2.62. The company had a trading volume of 124,158 shares, compared to its average volume of 1,029,288. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $16.55. The business's fifty day moving average is $2.25 and its two-hundred day moving average is $3.13.

Wall Street Analysts Forecast Growth

CATX has been the subject of a number of recent research reports. Royal Bank of Canada cut their target price on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Wedbush reissued an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $12.50.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.